The Phase I trial — meaning it is the first in humans and had the goal of showing the therapy is safe — examined 12 patients with gastrointestinal cancers, including colon and rectal cancer.

Herein, we present a summary of the FDA's review of the marketing application that led to the approval of nivolumab plus platinum-doublet chemotherapy as neoadjuvant therapy for patients ... American ...

In arm 1 of the trial, the dose-escalation portion, patients will receive mRNA-4106 at a test dose as monotherapy. In arm 2, ...

For example, patients who fail to achieve a pCR on neoadjuvant therapy are often considered for (more aggressive ... 28,29 In conclusion, we suggest that early response assessment in neoadjuvant ...

The study evaluates the feasibility, safety, and tolerability of neoadjuvant radiotherapy followed by a CDK4/6 inhibitor (dalpiciclib) and hormonal therapy in treatment-naive patients with unilateral ...

The objectives are as follows: To assess the effectiveness and safety of total neoadjuvant therapy versus standard therapy in individuals with locally advanced rectal cancer. This is a protocol. Was ...

German Cancer Consortium German Cancer Research Center, Heidelberg, Germany iDepartment of Radiation Oncology, Cyberknife and Radiation Therapy, University of Cologne, Faculty of Medicine and ...

Notably, the more aggressive breast cancer subtypes, including triple-negative and HER2-positive, have exhibited favorable responses to combined chemo-immunotherapy protocols. Neoadjuvant therapy has ...

is photographed, Oct. 14, 2015. (AP Photo/Andrew Harnik, File) WASHINGTON (AP) — U.S. regulators have approved the first cervical cancer testing kit that allows women to collect their own sample at ...

In early-stage estrogen receptor-positive (ER + ) breast cancer, resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) often involve a shift away from estrogen-driven proliferation. The ...

The Thursday nod—which covers patients who have already received systemic therapy—came coincidentally on World Ovarian Cancer Day and was more than seven weeks ahead of its June 30 FDA target ...